Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Castleman’s disease

Unicentric Form of Castleman Disease – Surgery Therapy Benefit International Registry for Patients With Castleman Disease A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman’s Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease Castleman Disease Collaborative Network Biobank Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease